OncoMatch/Neuroendocrine Tumor (NET)/MEN1

Neuroendocrine Tumor (NET)MEN1 Clinical Trials

1 recruiting trials·Updated daily from ClinicalTrials.gov

MEN1 mutations occur in approximately 35–40% of pancreatic NETs (pNETs) and define a subgroup with distinct epigenetic biology driven by menin loss. Loss of menin disrupts H3K4 methylation and epigenetic regulation. Trials investigate menin inhibitors (previously studied in MLL-rearranged leukemia) in MEN1-mutant pNETs, and the epigenetic landscape of MEN1-deficient NETs as a therapeutic vulnerability.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting MEN1 Neuroendocrine Tumor (NET) trials

Ranked by phase and US site count. See all 1 trials matched to your profile →

Phase 2

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other Neuroendocrine Tumor (NET) biomarkers

Browse other molecular targets with active Neuroendocrine Tumor (NET) trials.

SSTR (somatostatin receptor)

← All Neuroendocrine Tumor (NET) clinical trials